Cure8 trial brief
A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other therapies. Results could inform future larger trials and treatment options for people with UC.
Adults with moderately to severely active ulcerative colitis, clinicians managing UC, researchers in IBD drug development, and patients interested in oral anti‑integrin approaches or alternatives to injectable biologics.
This ClinicalTrials.gov record describes a completed Phase 2b randomized, double‑blind, placebo‑controlled trial testing MORF‑057 — an oral small molecule designed to selectively inhibit integrin α4β7 — in adults with moderately to severely active ulcerative colitis.
The study randomized participants to three active dosing regimens (200 mg BID, 100 mg BID, 100 mg QD morning) or matching placebo for a 12‑week induction period, with an option to switch to active drug during maintenance. Primary outcome was clinical remission by modified Mayo Clinic Score at Week 12.
Key eligibility points in the registry: adults 18–85 with at least 3 months of moderate–severe UC, prior inadequate response or intolerance to conventional and advanced therapies, and no prior exposure to approved or investigational anti‑integrin therapies. The record lists planned enrollment (~280) and multiple U.S. sites.
This summary is grounded in the ClinicalTrials.gov trial record and does not represent a review of full study results or peer‑reviewed publications.
This entry is a trial registry record (phase 2b, completed). The ClinicalTrials.gov page lists trial design, dosing arms, eligibility, and primary outcome but does not itself provide peer‑reviewed results; look for associated publications or sponsor disclosures for efficacy and safety findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
This registry entry describes a completed Phase 2 study of a new IV drug (tulisokibart) for moderate–severe ulcerative colitis, including safety endpoints and a companion diagnostic — information patients may want when...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
